QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

In most cases, Abbott is one of three or four competitors that dominate the market, including nutrition, cardiac rhythm management devices, surgical heart valves, continuous glucose monitors, coronary ...

The global HIV diagnostics market, valued at US$2.96B in 2024, is forecasted to grow at a 10.3% CAGR, reaching US$3.25B by ...

The demand for in situ hybridization is experiencing significant growth, mainly due to the rising rates of cancer and genetic disorders. This trend is further driven by the increasing incidence ...

Despite the dip, the company has still performed better than its peers, Exact Sciences EXAS and QIAGEN QGEN ... CoV-2 Assay is an in vitro diagnostic test that detects SARS-CoV-2 RNA from ...

Shah and colleagues take advantage of the presence of maternal and somatic ribosomes in zebrafish and confirm their differential expression during development. The authors convincingly show that ...

DELRAY BEACH, Fla., Feb. 28, 2025 /PRNewswire/ -- The global HIV diagnosis market, valued at US$2.96 billion in 2024, is forecasted to grow at a robust CAGR of 10.3%, reaching US$3.25 billion in 2025 ...

Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...